Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies/ml of HIV-RNA and > 500 x 106/l CD4 cells treated with highly active antiretroviral therapy

Massimo Andreoni, Saverio G. Parisi, Loredana Sarmati, Emanuele Nicastri, Lucia Ercoli, Giorgio Mancino, Giovanni Sotgiu, Marco Mannazzu, Marco Trevenzoli, Giuseppe Tridente, Ercole Concia, Antonio Aceti

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: To evaluate the decay rate of cellular proviral HIV-DNA and viral replication in patients receiving highly active antiretroviral therapy (HAART) in the very early phase of infection. Methods: Thirty-four patients treated with HAART and retrospectively selected for progressive decline of plasma viraemia up to undetectable levels (<20 copies/ml), were stratified according to CD4+ cell count and plasma viraemia at base line: > 500 x 106 cells/l with <5000 copies/ml (group 1) or with > 5000 copies/ml (group 2), > 5000 copies/ml with 300-500 x 106 cells/l (group 3) or with <300 x 106 cells/l (group 4). Plasma HIV-RNA and proviral HIV-DNA were analysed at baseline and after 1, 2, 3, 6, 9 and 12 months of treatment. Results: After 1 year of treatment, a significant decrease of proviral DNA titre was observed in all patients and a decrease > 1 log was achieved in 24 of 29 subjects of the first three groups. The more pronounced decay of HIV-DNA (half-life 28 weeks) up to <50 HIV-DNA copies/106 CD4+ cells was detected in patients of group 1. At the year's endpoint, five patients (four in group 1 and one in group 2) had <20 HIV-DNA copies. However, HIV strains sensitive to antiretroviral drugs were isolated from peripheral lymphocytes of 16 out of 34 patients. Conclusion: In patients with undetectable plasma viraemia after 1 year of HAART, the highest reduction of proviral DNA up to <50 copies/106 CD4+ cells was obtained only in subjects in the early asymptomatic phase of infection. Nevertheless, a replication-competent virus can be detected in all phases of antiretroviral therapy. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalAIDS (London, England)
Volume14
Issue number1
DOIs
Publication statusPublished - 2000

Fingerprint

Highly Active Antiretroviral Therapy
Viral DNA
HIV
Viremia
DNA
Asymptomatic Infections
Virus Replication
DNA Replication
Half-Life
Lymphocytes
Infection
Pharmaceutical Preparations

Keywords

  • Early treatment of HIV-infection
  • Highly active antiretroviral therapy
  • HIV isolation
  • Proviral HIV-DNA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies/ml of HIV-RNA and > 500 x 106/l CD4 cells treated with highly active antiretroviral therapy. / Andreoni, Massimo; Parisi, Saverio G.; Sarmati, Loredana; Nicastri, Emanuele; Ercoli, Lucia; Mancino, Giorgio; Sotgiu, Giovanni; Mannazzu, Marco; Trevenzoli, Marco; Tridente, Giuseppe; Concia, Ercole; Aceti, Antonio.

In: AIDS (London, England), Vol. 14, No. 1, 2000, p. 23-29.

Research output: Contribution to journalArticle

Andreoni, Massimo ; Parisi, Saverio G. ; Sarmati, Loredana ; Nicastri, Emanuele ; Ercoli, Lucia ; Mancino, Giorgio ; Sotgiu, Giovanni ; Mannazzu, Marco ; Trevenzoli, Marco ; Tridente, Giuseppe ; Concia, Ercole ; Aceti, Antonio. / Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies/ml of HIV-RNA and > 500 x 106/l CD4 cells treated with highly active antiretroviral therapy. In: AIDS (London, England). 2000 ; Vol. 14, No. 1. pp. 23-29.
@article{f7579b7110ec4f0f88b9fbb19ac6beec,
title = "Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies/ml of HIV-RNA and > 500 x 106/l CD4 cells treated with highly active antiretroviral therapy",
abstract = "Objective: To evaluate the decay rate of cellular proviral HIV-DNA and viral replication in patients receiving highly active antiretroviral therapy (HAART) in the very early phase of infection. Methods: Thirty-four patients treated with HAART and retrospectively selected for progressive decline of plasma viraemia up to undetectable levels (<20 copies/ml), were stratified according to CD4+ cell count and plasma viraemia at base line: > 500 x 106 cells/l with <5000 copies/ml (group 1) or with > 5000 copies/ml (group 2), > 5000 copies/ml with 300-500 x 106 cells/l (group 3) or with <300 x 106 cells/l (group 4). Plasma HIV-RNA and proviral HIV-DNA were analysed at baseline and after 1, 2, 3, 6, 9 and 12 months of treatment. Results: After 1 year of treatment, a significant decrease of proviral DNA titre was observed in all patients and a decrease > 1 log was achieved in 24 of 29 subjects of the first three groups. The more pronounced decay of HIV-DNA (half-life 28 weeks) up to <50 HIV-DNA copies/106 CD4+ cells was detected in patients of group 1. At the year's endpoint, five patients (four in group 1 and one in group 2) had <20 HIV-DNA copies. However, HIV strains sensitive to antiretroviral drugs were isolated from peripheral lymphocytes of 16 out of 34 patients. Conclusion: In patients with undetectable plasma viraemia after 1 year of HAART, the highest reduction of proviral DNA up to <50 copies/106 CD4+ cells was obtained only in subjects in the early asymptomatic phase of infection. Nevertheless, a replication-competent virus can be detected in all phases of antiretroviral therapy. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Early treatment of HIV-infection, Highly active antiretroviral therapy, HIV isolation, Proviral HIV-DNA",
author = "Massimo Andreoni and Parisi, {Saverio G.} and Loredana Sarmati and Emanuele Nicastri and Lucia Ercoli and Giorgio Mancino and Giovanni Sotgiu and Marco Mannazzu and Marco Trevenzoli and Giuseppe Tridente and Ercole Concia and Antonio Aceti",
year = "2000",
doi = "10.1097/00002030-200001070-00003",
language = "English",
volume = "14",
pages = "23--29",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies/ml of HIV-RNA and > 500 x 106/l CD4 cells treated with highly active antiretroviral therapy

AU - Andreoni, Massimo

AU - Parisi, Saverio G.

AU - Sarmati, Loredana

AU - Nicastri, Emanuele

AU - Ercoli, Lucia

AU - Mancino, Giorgio

AU - Sotgiu, Giovanni

AU - Mannazzu, Marco

AU - Trevenzoli, Marco

AU - Tridente, Giuseppe

AU - Concia, Ercole

AU - Aceti, Antonio

PY - 2000

Y1 - 2000

N2 - Objective: To evaluate the decay rate of cellular proviral HIV-DNA and viral replication in patients receiving highly active antiretroviral therapy (HAART) in the very early phase of infection. Methods: Thirty-four patients treated with HAART and retrospectively selected for progressive decline of plasma viraemia up to undetectable levels (<20 copies/ml), were stratified according to CD4+ cell count and plasma viraemia at base line: > 500 x 106 cells/l with <5000 copies/ml (group 1) or with > 5000 copies/ml (group 2), > 5000 copies/ml with 300-500 x 106 cells/l (group 3) or with <300 x 106 cells/l (group 4). Plasma HIV-RNA and proviral HIV-DNA were analysed at baseline and after 1, 2, 3, 6, 9 and 12 months of treatment. Results: After 1 year of treatment, a significant decrease of proviral DNA titre was observed in all patients and a decrease > 1 log was achieved in 24 of 29 subjects of the first three groups. The more pronounced decay of HIV-DNA (half-life 28 weeks) up to <50 HIV-DNA copies/106 CD4+ cells was detected in patients of group 1. At the year's endpoint, five patients (four in group 1 and one in group 2) had <20 HIV-DNA copies. However, HIV strains sensitive to antiretroviral drugs were isolated from peripheral lymphocytes of 16 out of 34 patients. Conclusion: In patients with undetectable plasma viraemia after 1 year of HAART, the highest reduction of proviral DNA up to <50 copies/106 CD4+ cells was obtained only in subjects in the early asymptomatic phase of infection. Nevertheless, a replication-competent virus can be detected in all phases of antiretroviral therapy. (C) 2000 Lippincott Williams and Wilkins.

AB - Objective: To evaluate the decay rate of cellular proviral HIV-DNA and viral replication in patients receiving highly active antiretroviral therapy (HAART) in the very early phase of infection. Methods: Thirty-four patients treated with HAART and retrospectively selected for progressive decline of plasma viraemia up to undetectable levels (<20 copies/ml), were stratified according to CD4+ cell count and plasma viraemia at base line: > 500 x 106 cells/l with <5000 copies/ml (group 1) or with > 5000 copies/ml (group 2), > 5000 copies/ml with 300-500 x 106 cells/l (group 3) or with <300 x 106 cells/l (group 4). Plasma HIV-RNA and proviral HIV-DNA were analysed at baseline and after 1, 2, 3, 6, 9 and 12 months of treatment. Results: After 1 year of treatment, a significant decrease of proviral DNA titre was observed in all patients and a decrease > 1 log was achieved in 24 of 29 subjects of the first three groups. The more pronounced decay of HIV-DNA (half-life 28 weeks) up to <50 HIV-DNA copies/106 CD4+ cells was detected in patients of group 1. At the year's endpoint, five patients (four in group 1 and one in group 2) had <20 HIV-DNA copies. However, HIV strains sensitive to antiretroviral drugs were isolated from peripheral lymphocytes of 16 out of 34 patients. Conclusion: In patients with undetectable plasma viraemia after 1 year of HAART, the highest reduction of proviral DNA up to <50 copies/106 CD4+ cells was obtained only in subjects in the early asymptomatic phase of infection. Nevertheless, a replication-competent virus can be detected in all phases of antiretroviral therapy. (C) 2000 Lippincott Williams and Wilkins.

KW - Early treatment of HIV-infection

KW - Highly active antiretroviral therapy

KW - HIV isolation

KW - Proviral HIV-DNA

UR - http://www.scopus.com/inward/record.url?scp=0033971567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033971567&partnerID=8YFLogxK

U2 - 10.1097/00002030-200001070-00003

DO - 10.1097/00002030-200001070-00003

M3 - Article

C2 - 10714564

AN - SCOPUS:0033971567

VL - 14

SP - 23

EP - 29

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 1

ER -